|
Laboratory and continuous veno-venous hemofiltration (CVVH) parameters |
|||
| PF4+ (n = 7) |
PF4- (n = 21) |
P value |
|
|
|
|||
| Creatinine before first CVVH, μmol/L |
600 (247–742) |
403 (312–441) |
0.34 |
| Urea before first CVVH, mmol/L |
17 (10–25) |
15 (12–24) |
0.91 |
| Number of CVVH sessions |
5 (4–11) |
5 (3–9) |
0.65 |
| Mean CVVH durationa, hours |
10.4 (9.6–18–4) |
22.7 (15.7–22.3) |
0.03 |
| Mean urea reduction ratiosa, percentage |
17 (10–37) |
44 (30–52) |
0.04 |
| Platelet nadir, 109/L |
40 (24–46) |
35 (17–43) |
0.54 |
| Maximum platelet count, 109/L |
324 (238–366) |
286 (182–403) |
0.81 |
| PF4 platelet count variation (D0-DPF4), percentage |
59 (35–73) |
56 (35–73) |
0.98 |
| Maximum platelet count variation (D0-Dnadir), percentage |
77 (49–81) |
79 (55–87) |
0.81 |
| Mean minimum aPTT ratiosb |
1.20 (1.12–1.22) |
1.35 (1.10–1.56) |
0.35 |
| Mean maximum aPTT ratiosb |
1.85 (1.65–2.12) |
2.19 (1.51–2.93) |
0.35 |
|
Platelet count variations were calculated as follows: [(platelet D0 – platelet Dx)/platelet D0] × 100, where platelet D0 is the platelet count on admission and platelet Dx is the platelet count on the day of anti-PF4/heparin antibody assay (DPF4) or the minimal platelet count (Dnadir). Results are expressed as median (first quartile to third quartile). aFor PF4+ patients, mean duration and efficiency of CVVH sessions before replacement of unfractionated heparin by danaparoid; bmeans of minimum and maximum aPTT ratios observed during all the CVVH sessions before DPF4. aPTT, activated partial thromboplastin time (on heparin therapy during all continuous veno-venous hemofiltration sessions); PF4-, anti-PF4/heparin antibody-negative; PF4+, anti-PF4/heparin antibody-positive. | |||
Lasocki et al. Critical Care 2008 12:R84 doi:10.1186/cc6937 |
|||